Recently, a phase 2 clinical trial has shown that administration of the ATR inhibitor berzosertib with gemcitabine increased progression-free survival in patients with high-grade ovarian cancer compared with gemcitabine alone 40, suggesting that ATR inhibitor is beneficial for ovarian cancer therapy. The gene discussed is ATR; the disease is ovarian cancer.